Stoke Therapeutics, Inc.
STOK- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001623526
In the last 90 days, Stoke Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 197 institutions reported holding it in 13F filings for Q2 2026, worth $2.49B in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Stoke Therapeutics, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 198
- +17 vs. Q4 2025
- Shares held
- 71.1M
- +7.28M (+11.4%) vs. Q4 2025
- Total value
- $2.31B
- +$288.8M (+14.3%) vs. Q4 2025
- New holders
- 44
- 80 more added
- Sold out
- 27
- 52 more reduced
2 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting STOK on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 197 | $2.49B |
| Q1 2026 | 198 | $2.31B |
| Q4 2025 | 183 | $2.13B |
| Q3 2025 | 151 | $1.57B |
| Q2 2025 | 134 | $744.0M |
| Q1 2025 | 126 | $421.6M |
| Q4 2024 | 130 | $640.4M |
| Q3 2024 | 118 | $715.5M |
| Q2 2024 | 115 | $828.5M |
| Q1 2024 | 103 | $731.7M |
| Q4 2023 | 81 | $236.9M |
| Q3 2023 | 97 | $173.1M |
| Q2 2023 | 100 | $494.8M |
| Q1 2023 | 97 | $371.8M |
| Q4 2022 | 107 | $371.8M |
| Q3 2022 | 105 | $544.4M |
| Q2 2022 | 92 | $569.4M |
| Q1 2022 | 99 | $870.6M |
| Q4 2021 | 94 | $849.6M |
| Q3 2021 | 90 | $492.4M |
| Q2 2021 | 97 | $680.3M |
| Q1 2021 | 106 | $1.49B |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Stoke Therapeutics, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Alyeska Investment Group, L.P. | 0 | $0 | 0.00% | −75,000−100.0% | Sold out |
| Kennondale Capital Management LLC | 0 | $0 | 0.00% | −38,731−100.0% | Sold out |
| Readystate Asset Management LP | 0 | $0 | 0.00% | −29,059−100.0% | Sold out |
| Tudor Investment Corp Et Al | 0 | $0 | 0.00% | −19,309−100.0% | Sold out |
| Diadema Partners LP | 0 | $0 | 0.00% | −17,181−100.0% | Sold out |
| Quest Partners LLC | 0 | $0 | 0.00% | −15,036−100.0% | Sold out |
| Jacobs Levy Equity Management, Inc | 0 | $0 | 0.00% | −12,878−100.0% | Sold out |
| Entropy Technologies, LP | 0 | $0 | 0.00% | −11,764−100.0% | Sold out |
| Capital Fund Management S.A. | 0 | $0 | 0.00% | −11,717−100.0% | Sold out |
| GWM Advisors LLC | 0 | $0 | 0.00% | −10,403−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −9,055−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −8,054−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −7,076−100.0% | Sold out |
| J. Goldman & Co LP | 0 | $0 | 0.00% | −6,827−100.0% | Sold out |
| Prelude Capital Management, LLC | 0 | $0 | 0.00% | −6,369−100.0% | Sold out |
| Persistent Asset Partners Ltd | 0 | $0 | 0.00% | −4,576−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −4,110−100.0% | Sold out |
| CFG Wealth Management Services, Inc. | 0 | $0 | 0.00% | −2,230−100.0% | Sold out |
| Amalgamated Bank | 0 | $0 | 0.00% | −1,409−100.0% | Sold out |
| Kestra Advisory Services, LLC | 0 | $0 | 0.00% | −818−100.0% | Sold out |
| Montag A & Associates Inc | 0 | $0 | 0.00% | −440−100.0% | Sold out |
| Daiwa Securities Group Inc. | 0 | $0 | 0.00% | −175−100.0% | Sold out |
| Optiver Holding B.V. | 0 | $0 | 0.00% | −142−100.0% | Sold out |
| Quantbot Technologies LP | 0 | $0 | 0.00% | −88−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −21−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |
| Global Retirement Partners, LLC | – | – | – | – | Not filed |